Cardiovascular disease continues to be the leading cause of death worldwide. But advances in heart-failure therapeutics have ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Moderna (MRNA) is scheduled to announce Q3 earnings results on November 6, before market open, with analysts’ consensus ...

The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Scientists have developed an experimental mRNA vaccine that, when combined with existing immunotherapy drugs, could 'teach' the immune system to recog ...

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of ...

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors. Research reported recently in the journal Nature ...

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the ...

Yale researchers have developed a new vaccine that does double duty against a rare and aggressive skin cancer by targeting ...